79 related articles for article (PubMed ID: 10348800)
1. Cardiovascular effect and simultaneous pharmacokinetic and pharmacodynamic modeling of pimobendan in healthy normal subjects.
Chu KM; Hu OY; Shieh SM
Drug Metab Dispos; 1999 Jun; 27(6):701-9. PubMed ID: 10348800
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing.
Chu KM; Shieh SM; Hu OY
Clin Pharmacol Ther; 1995 Jun; 57(6):610-21. PubMed ID: 7781260
[TBL] [Abstract][Full Text] [Related]
3. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals.
Sundberg S; Antila S; Scheinin H; Häyhä M; Virtanen M; Lehtonen L
Int J Clin Pharmacol Ther; 1998 Dec; 36(12):629-35. PubMed ID: 9876999
[TBL] [Abstract][Full Text] [Related]
4. Hemodynamic profile of the cardiotonic agent pimobendan.
van Meel JC; Diederen W
J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S1-6. PubMed ID: 2478784
[TBL] [Abstract][Full Text] [Related]
5. Plasma and red blood cell pharmacokinetics of pimobendan enantiomers in healthy Chinese.
Chu KM; Shieh SM; Hu OY
Eur J Clin Pharmacol; 1995; 47(6):537-42. PubMed ID: 7768258
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of oral pimobendan in healthy cats.
Hanzlicek AS; Gehring R; Kukanich B; Kukanich KS; Borgarelli M; Smee N; Olson EE; Margiocco M
J Vet Cardiol; 2012 Dec; 14(4):489-96. PubMed ID: 23116650
[TBL] [Abstract][Full Text] [Related]
7. Correlations between the cardiovascular effects of pimobendan and plasma concentrations of the parent compound and of its major active metabolite, UD-CG 212 CL, in patients with congestive heart failure.
Hagemeijer F; Roth W; Brand HJ
J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S57-64. PubMed ID: 2478794
[TBL] [Abstract][Full Text] [Related]
8. Use of the novel cardiotonic and vasodilator agent pimobendan in traumatic shock.
Bitterman H; Smith BA; Lefer AM
Arzneimittelforschung; 1988 Oct; 38(10):1389-93. PubMed ID: 3196378
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.
Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J
Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544
[TBL] [Abstract][Full Text] [Related]
10. Inotropic effects of a single intravenous recommended dose of pimobendan in healthy dogs.
Hori Y; Taira H; Nakajima Y; Ishikawa Y; Yumoto Y; Maekawa Y; Oshiro A
J Vet Med Sci; 2019 Jan; 81(1):22-25. PubMed ID: 30404952
[TBL] [Abstract][Full Text] [Related]
11. Single-dose pharmacokinetics and cardiovascular effects of oral pimobendan in healthy cats.
Yata M; McLachlan AJ; Foster DJ; Hanzlicek AS; Beijerink NJ
J Vet Cardiol; 2016 Dec; 18(4):310-325. PubMed ID: 27613648
[TBL] [Abstract][Full Text] [Related]
12. Acute pharmacodynamic effects of pimobendan in client-owned cats with subclinical hypertrophic cardiomyopathy.
Oldach MS; Ueda Y; Ontiveros ES; Fousse SL; Visser LC; Stern JA
BMC Vet Res; 2021 Feb; 17(1):89. PubMed ID: 33622315
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics of pimobendan enantiomers after oral and intravenous administration of racemate pimobendan formulations in healthy dogs.
Bell ET; Devi JL; Chiu S; Zahra P; Whittem T
J Vet Pharmacol Ther; 2016 Feb; 39(1):54-61. PubMed ID: 25989021
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans.
Woo SK; Kang WK; Kwon KI
Clin Pharmacol Ther; 2002 Apr; 71(4):246-52. PubMed ID: 11956507
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and cardiovascular effects following a single oral administration of a nonaqueous pimobendan solution in healthy dogs.
Yata M; McLachlan AJ; Foster DJ; Page SW; Beijerink NJ
J Vet Pharmacol Ther; 2016 Feb; 39(1):45-53. PubMed ID: 25997373
[TBL] [Abstract][Full Text] [Related]
16. Identification of cytochrome P-450 isoform(s) responsible for the metabolism of pimobendan in human liver microsomes.
Kuriya Si; Ohmori S; Hino M; Ishii I; Nakamura H; Senda C; Igarashi T; Kiuchi M; Kitada M
Drug Metab Dispos; 2000 Jan; 28(1):73-8. PubMed ID: 10611143
[TBL] [Abstract][Full Text] [Related]
17. Acute hemodynamics of pimobendan in chronic heart failure. A comparative crossover study of captopril and pimobendan.
Tsuda T; Izumi T; Kodama M; Hanawa H; Takahashi M; Suzuki M; Aizaki T; Uchiyama H; Kuwano H; Shibata A
Jpn Heart J; 1992 Mar; 33(2):193-203. PubMed ID: 1593749
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a new renin inhibitor). I: Single dose study.
Gupta SK; Granneman GR; Boger RS; Hollenberg NK; Luther RR
Drug Metab Dispos; 1992; 20(6):821-5. PubMed ID: 1362933
[TBL] [Abstract][Full Text] [Related]
19. Effect of pimobendan on cardiopulmonary baroreflex control of sympathetic nerve activity in healthy young men.
Maruyama M; Takamura M; Takata S; Murai H; Usui S; Furusho H; Sakagami S; Yuasa T; Shimakura A; Kaneko S
Auton Neurosci; 2005 Oct; 122(1-2):100-6. PubMed ID: 16199209
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of pimobendan in long-term human hepatocyte culture: in vivo-in vitro comparison.
Pahernik SA; Schmid J; Sauter T; Schildberg FW; Koebe HG
Xenobiotica; 1995 Aug; 25(8):811-23. PubMed ID: 8779223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
